1017-06-7

Basic information

• Product Name: 4,5-Dihydro-6-(4-methoxyphenyl)pyridazin-3(2H)-one
• Synonyms: 2,3,4,5-Tetrahydro-6-(4-methoxyphenyl)-3-pyridazinone;6-(4-Methoxyphenyl)-4,5-dihydro-2H-pyridazin-3-one
• CAS NO: 1017-06-7
• Molecular Formula: C₁₁H₁₂N₂O₂
• Molecular Weight: 204.23
• Mol File: 1017-06-7.mol
• Article Data: 22

Chemical Properties

• Melting Point: 150-151℃
• Appearance: /
• Density: 1.23
• Refractive Index: 1.598
• CAS DataBase Reference: 4,5-Dihydro-6-(4-methoxyphenyl)pyridazin-3(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-Dihydro-6-(4-methoxyphenyl)pyridazin-3(2H)-one(1017-06-7)
• EPA Substance Registry System: 4,5-Dihydro-6-(4-methoxyphenyl)pyridazin-3(2H)-one(1017-06-7)

Safety Data

• Hazardous Substances Data: 1017-06-7(Hazardous Substances Data)

Usage

General Description

4,5-Dihydro-6-(4-methoxyphenyl)pyridazin-3(2H)-one is a chemical compound with the molecular formula C12H12N2O2. It belongs to the class of pyridazine derivatives and is a heterocyclic organic compound. This chemical has a pyridazin-3-one core structure with a 4-methoxyphenyl group attached to the 6th position, and a dihydro group at the 4th and 5th positions. It is used in medicinal chemistry and pharmaceutical research for its potential pharmacological and biological activities. The compound may have applications in drug development due to its structural properties and potential therapeutic effects.

InChI:InChI=1/C11H12N2O2/c1-15-9-4-2-8(3-5-9)10-6-7-11(14)13-12-10/h2-5H,6-7H2,1H3,(H,13,14)

Upstream product

• 3153-44-4 4-(4-methoxy-phenyl)-4-oxo-butyric acid 
• 60112-44-9 5-(4-methoxyphenyl)furan-2(3H)-one 
• 1010800-67-5 tert-butyl 4-(4-methoxyphenyl)-4-oxobutanoate 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 38102-67-9 4-(3-methoxy-phenyl)-4-oxo-butyric acid 
• 100-66-3 methoxybenzene 
• 5447-74-5 methyl 3-(4-methoxybenzoyl)propionate 

Downstream Products

• 142731-44-0 [3-(4-Methoxy-phenyl)-6-oxo-5,6-dihydro-4H-pyridazin-1-yl]-acetic acid methyl ester 
• 76617-83-9 6-(4-Methoxy-phenyl)-6-phenyl-tetrahydro-pyridazin-3-one 
• 2166-33-8 6-(4-methoxyphenyl)-2H-pyridazin-3-one 
• 74190-69-5 3-(4-methoxyphenyl)-1,4,5,6-tetrahydropyridazine 
• 282090-13-5 3-[6-(4-methoxyphenyl)-3(2H)-pyridazinon-2-yl]propanenitrile 
• 129904-89-8 [6-(4-methoxyphenyl)-3(2H)-pyridazinon-2-yl]acetic acid 
• 282090-12-4 3-[6-(4-methoxyphenyl)-3(2H)-pyridazinon-2-yl]propanoic acid 
• 133342-12-8 ethyl [6-(4-methoxyphenyl)-3(2H)-pyridazinon-2-yl]acetate 

Relevant articles and documents

Synthesis, anti-convulsant activity and molecular docking study of novel thiazole pyridazinone hybrid analogues

Pyridazinone analogues have been known to be potential candidates for anticonvulsant agents. We have identified several pyridazinone-based anticonvulsant agents. As a continuation to our previous research, a series of hybrid pyridazinone-thiazole connected through amide linkage were designed and synthesized. Among these, compound SP-5F demonstrated significant anticonvulsant activity with median effective dose of 24.38 mg/kg (MES) and 88.23 mg/kg (scPTz). Results of GABA estimation showed a marked increase in the GABA level when compared with control. Molecular docking studies at the active site of GABA receptor, further confirmed the GABA modulatory effects of SP-5F.

PRODUCING METHOD OF NITROGEN-CONTAINING ORGANIC COMPOUND

A hydrazine-carbon dioxide-binding compound or hydrazine derivatives 2 carbonyl group react with a compound having one or more nitrogen-containing organic for preparing the compounds of relates to method.

Design, synthesis and antihypertensive screening of novel pyridazine substituted s-triazin-2-imine/one/thione derivatives

Some new 7-substituted-phenyl-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-imine/one/thione derivatives were synthesized by a sequence of reactions starting from appropriate aryl hydrocarbons. The final compounds were screened for antihypertensive activities by non-invasive method using Tail Cuff method. All the test compounds showed significant antihypertensive activity; 7-(biphenyl-4-yl)-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-imine (4p) exhibited antihypertensive activity more than the reference standard drugs.